No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies based on ribonucleic acid interference (RNAi) technology. The company's diverse pipeline of experimental RNAi therapeutics addresses a variety of serious conditions, including inherited genetic disorders, cardiometabolic ailments, hepatic infectious diseases, and diseases affecting the central nervous system (CNS) and eyes. Currently, Alnylam markets several key products: ONPATTRO (patisiran), an injection for adults suffering from polyneuropathy due to hereditary transthyretin-mediated amyloidosis; GIVLAARI, approved for the treatment of acute hepatic porphyria (AHP) in adults; and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial offerings, Alnylam is actively advancing numerous drug candidates. These include givosiran for adolescent AHP, patisiran for transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy, and cemdisiran for complement-mediated diseases. Other investigational therapies in development are ALN-AAT02 for AAT deficiency-associated liver disease, ALN-HBV02 for chronic hepatitis B infection, Zilebesiran for hypertension, and ALN-HSD for nonalcoholic steatohepatitis (NASH). Additionally, the company is developing Fitusiran for hemophilia and rare bleeding disorders, Inclisiran for hypercholesterolemia, lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran, which is in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals also maintains strategic collaborations, notably with Regeneron Pharmaceuticals, Inc., to identify, develop, and commercialize RNAi therapeutics targeting ocular and CNS diseases, and with Sanofi Genzyme for broader RNAi therapeutic discovery and development. The company also holds licensing and collaboration agreements with several other entities, including Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Founded in 2002, Alnylam Pharmaceuticals, Inc. operates from its headquarters in Cambridge, Massachusetts.
www.alnylam.comNo one on the platform currently holds DUL.DE.
No tracked institution reports a position in DUL.DE as of their last filing.
No one on the platform has traded DUL.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 20.9% | — | — | — | ||
| Rev. Growth % | 65.2% | 49.8% | ||||
| Profit Margin % | 8.4% | -47.6% | -324.8% | |||
| Free Cash Flow Margin % | 12.5% | -26.2% | -271.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.4B | +43.5% | $6.58 | $5.92–$7.48 | — | 1 |
| 2027 | $6.8B | +26.9% | $9.93 | $8.95–$11.30 | — | 1 |
| 2028 | $8.2B | +19.6% | $12.34 | $11.11–$14.03 | — | 1 |
| 2029 | $9.2B | +12.5% | $14.17 | $12.76–$16.11 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.43 | $1.06 | -25.9% |
| 2026-04-30 | $0.75 | $1.31 | +73.7% |
| 2026-02-12 | $0.98 | $0.70 | -29.1% |
| 2025-10-30 | $0.48 | $1.33 | +178.2% |
| 2025-07-31 | $-0.46 | $-0.43 | +6.2% |
| 2025-05-01 | $-0.82 | $-0.41 | +50.6% |
| $47.9B |
| — |
| CGN.DECigna Corporation | $250.80 | +0.08% | $66.3B | — |
| MRK.DEMerck KGaA | $130.90 | +0.27% | $56.9B | — |
Source: Financial Modeling Prep · peers by sector/industry